Renal Cell Carcinoma
📧 Sign up to get email alerts when something new happens for Renal Cell Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-05-06Clinical Trial Update: Vascular Endothelial Growth Factor (VEGF) Imaging Before and During Everolimus Treatment for Renal Cell Carcinoma
A completed clinical trial evaluating VEGF imaging before and during everolimus treatment for metastatic renal cell carcinoma.
-
CLINICAL_TRIALS research · 2024-05-06Clinical Trial Update: Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease
This clinical trial update describes a completed University Medical Center Groningen study on visualizing VEGF-producing lesions associated …
-
CLINICAL_TRIALS research · 2024-05-01Clinical Trial Update: Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors [Phase 1]
Phase 1 trial evaluating the combination of 177Lu-TLX250 and Peposertib in CAIX-expressing solid tumors; currently recruiting.
-
FDA approval · 2024-04-30FDA Approved: EVEROLIMUS — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for Everolimus submitted by Hikma Pharmaceuticals USA Inc. This action updates approved labeling…
-
CLINICAL_TRIALS research · 2024-04-30Clinical Trial Update: Establishment of a Multidimensional Prediction Model for the Natural Course of VHL Disease-related Renal Cell Carcinoma
An ongoing clinical study at Peking University First Hospital to develop a multidimensional prediction model for the natural history of von …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2024-04-26Clinical Trial Update: Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells Cancer [Phase 2]
A Phase 2 trial of cabozantinib before cytoreductive nephrectomy in advanced or metastatic renal cell carcinoma was terminated.
-
CLINICAL_TRIALS withdrawal · 2024-04-26Clinical Trial Update: Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary [Phase 1]
A Phase 1 trial evaluating nivolumab plus ipilimumab with immunostimulatory embolization for stage IV renal cell carcinoma with an unresecte…
-
CLINICAL_TRIALS trial_result · 2024-04-25Clinical Trial Update: Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy [Phase 3]
This Phase 3 clinical trial update reports results for nivolumab in localized renal cell carcinoma patients undergoing nephrectomy, with the…
-
CLINICAL_TRIALS trial_result · 2024-04-25Clinical Trial Update: Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy [Phase 3]
Phase 3 trial update evaluating nivolumab in patients with localized kidney cancer undergoing nephrectomy; status ACTIVE_NOT_RECRUITING with…
-
CLINICAL_TRIALS research · 2024-04-25Clinical Trial Update: A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors [Phase 1]
This is a Phase 1 clinical trial studying Anti-CD70 UCAR-T for relapsed or refractory solid tumors, with not yet recruiting status.
-
FDA approval · 2024-04-23FDA Approved: PAZOPANIB — Original Application (Novugen Pharma (USA) LLC.)
FDA approved pazopanib hydrochloride as an original ANDA, enabling a generic version of pazopanib.
-
CLINICAL_TRIALS trial_result · 2024-04-18Clinical Trial Update: A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors [Phase 1, Phase 2]
Phase 1/2 trial of DSP-7888 Dosing Emulsion in combination with immune checkpoint inhibitors in adults with advanced solid tumors was termin…
-
CLINICAL_TRIALS trial_result · 2024-04-09Clinical Trial Update: Sintilimab Injection Combined With Inlyta in Fumarate Hydratase- Deficient Renal Cell Carcinoma [Phase 2]
Phase 2 trial evaluating sintilimab in combination with Inlyta for fumarate hydratase-deficient renal cell carcinoma is currently active but…
-
CLINICAL_TRIALS trial_result · 2024-03-20Clinical Trial Update: Microwave Ablation With MRI-Guided SBRT Boost in Renal Cell Carcinoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating microwave ablation with MRI-guided SBRT boost for renal cell carcinoma; study terminated with results posted in 2…
-
CLINICAL_TRIALS trial_result · 2024-03-18Clinical Trial Update: Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab [Phase 2]
Phase 2 trial update evaluating intermittent therapy in metastatic renal cell carcinoma patients treated with ipilimumab and nivolumab.
-
CLINICAL_TRIALS trial_result · 2024-03-15Clinical Trial Update: A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors [Phase 1, Phase 2]
Clinical trial update for a study evaluating safety, efficacy, and pharmacokinetics in participants with advanced solid tumors, including re…
-
CLINICAL_TRIALS trial_result · 2024-03-08Clinical Trial Update: Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta in South Korea
Post-marketing surveillance study assessing safety and efficacy of Inlyta in South Korea for advanced renal cell carcinoma; study completed …
-
CLINICAL_TRIALS trial_result · 2024-03-06Clinical Trial Update: Adaptive Staged Stereotactic Body Radiation Therapy in Treating Patients With Spinal Metastases That Cannot Be Removed by Surgery [NA]
Clinical trial update for adaptive staged stereotactic body radiation therapy in patients with spinal metastases, completed with posted resu…
-
FDA approval · 2024-03-05FDA Approved: SORAFENIB TOSYLATE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA granted a supplemental approval for sorafenib tosylate (generic sorafenib) by Mylan Pharmaceuticals Inc., allowing the generic product t…
-
CLINICAL_TRIALS trial_result · 2024-03-04Clinical Trial Update: Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer [Phase 2]
A Phase 2 clinical trial evaluating a monoclonal antibody therapy for advanced kidney cancer (renal cell carcinoma) has completed.
-
CLINICAL_TRIALS trial_result · 2024-03-01Clinical Trial Update: A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma [Phase 2]
This Phase 2 trial evaluating NIR178 in combination with PDR001 across multiple solid tumors and non-Hodgkin lymphoma was terminated, with r…
-
CLINICAL_TRIALS trial_result · 2024-02-28Clinical Trial Update: A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013) [Phase 2]
Phase 2 study of belzutifan (MK-6482) in participants with advanced renal cell carcinoma; results have been posted and the trial is currentl…
-
CLINICAL_TRIALS trial_result · 2024-02-28Clinical Trial Update: A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment [Phase 3]
Phase 3 study comparing atezolizumab plus cabozantinib versus cabozantinib alone in advanced renal cell carcinoma after prior immune checkpo…
-
CLINICAL_TRIALS trial_result · 2024-02-28Clinical Trial Update: Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types [Phase 2]
Phase 2 trial update reporting access to nivolumab for adults with selected rare cancer types; study completed.
-
CLINICAL_TRIALS trial_result · 2024-01-23Clinical Trial Update: CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors [Phase 2]
Phase 2 trial evaluating checkpoint inhibition in combination with external beam radiotherapy for solid tumors; study is completed.